Paulo Fontoura

Citado por

	Total	Desde 2019
Citas	12065	7648
Índice h	38	30
Índice i10	69	49

1800

900

450

1350

200320042005200620072008200920102011201220132014201520162017201820192020202120222023202450 62 94 121 180 173 167 162 165 191 238 250 303 393 707 949 1060 1122 1378 1671 1776 619

Acceso público

Ver todo

22 artículos

3 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

lawrence steinmanstanford universityDirección de correo verificada de stanford.edu
Ludwig KapposUniversity Hospital BaselDirección de correo verificada de uhbs.ch
Amit Bar-OrProfessor, University of PennsylvaniaDirección de correo verificada de pennmedicine.upenn.edu
Stephen L. HauserUCSFDirección de correo verificada de ucsf.edu
Fred LublinIcahn School of Medicine at Mount SinaiDirección de correo verificada de mssm.edu
Jerry S Wolinsky, MDEmeritus Professor in Neurology, McGovern Medical School, UTHealth, The University of Texas HealthDirección de correo verificada de uth.tmc.edu
Xavier MontalbanDirección de correo verificada de cem-cat.org
Gavin GiovannoniBarts and The London School of Medicine and DentistryDirección de correo verificada de giovannoni.net
Bernhard HemmerTechnical University of MunichDirección de correo verificada de tum.de
Omar KhwajaVoyager TherapeuticsDirección de correo verificada de vygr.com
Daniel UmbrichtF. Hoffmann - La Roche Ltd, University of ZurichDirección de correo verificada de roche.com
Geoffrey A. KerchnerVP and Head of Early Development, Neuroscience & Rare Diseases, F. Hoffmann-La Roche, Ltd., BaselDirección de correo verificada de roche.com
Mercè Boada, MD, PhDNeuróloga. MD, PhDDirección de correo verificada de fundacioace.com
Shibeshih Mitiku BelachewBiogenDirección de correo verificada de biogen.com
Marta del Valle RubidoDirección de correo verificada de roche.com
Philip ScheltensProfessor of NeurologyDirección de correo verificada de amsterdamumc.nl
Eugenio MercuriCatholic UniversityDirección de correo verificada de unicatt.it
Douglas Lorne Arnold, MD, FRCP(C)James McGill Professor: Department of Neurology and Neurosurgery, Faculty of Medicine, McGillDirección de correo verificada de mcgill.ca
Frederik BarkhofVU University Medical CenterDirección de correo verificada de vumc.nl
bruno duboisDirección de correo verificada de aphp.fr

Seguir

Paulo Fontoura

Global Head of Neuroscience, Roche Pharmaceuticals

Dirección de correo verificada de roche.com

Neuroscience


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017	1879	2017
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017	1779	2017
The Parkinson progression marker initiative (PPMI) K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ... Progress in neurobiology 95 (4), 629-635, 2011	1483	2011
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy NA Naryshkin, M Weetall, A Dakka, J Narasimhan, X Zhao, Z Feng, ... science 345 (6197), 688-693, 2014	546	2014
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite M Platten, PP Ho, S Youssef, P Fontoura, H Garren, EM Hur, R Gupta, ... Science 310 (5749), 850-855, 2005	517	2005
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease S Ostrowitzki, RA Lasser, E Dorflinger, P Scheltens, F Barkhof, ... Alzheimer's research & therapy 9, 1-15, 2017	469	2017
The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis V Devonshire, Y Lapierre, R Macdonell, C Ramo‐Tello, F Patti, ... European Journal of Neurology 18 (1), 69-77, 2011	415	2011
Heme oxygenase–1 and carbon monoxide suppress autoimmune neuroinflammation ÂA Chora, P Fontoura, A Cunha, TF Pais, S Cardoso, PP Ho, LY Lee, ... The Journal of clinical investigation 117 (2), 438-447, 2007	362	2007
Risdiplam in type 1 spinal muscular atrophy G Baranello, BT Darras, JW Day, N Deconinck, A Klein, R Masson, ... New England Journal of Medicine 384 (10), 915-923, 2021	294	2021
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis WH Robinson, P Fontoura, BJ Lee, HEN De Vegvar, J Tom, R Pedotti, ... Nature biotechnology 21 (9), 1033-1039, 2003	294	2003
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review A Langer-Gould, RA Popat, SM Huang, K Cobb, P Fontoura, MK Gould, ... Archives of neurology 63 (12), 1686-1691, 2006	281	2006
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease S Salloway, M Farlow, E McDade, DB Clifford, G Wang, JJ Llibre-Guerra, ... Nature medicine 27 (7), 1187-1196, 2021	221	2021
Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway H Garren, PJ Ruiz, TA Watkins, P Fontoura, LVT Nguyen, ER Estline, ... Immunity 15 (1), 15-22, 2001	186	2001
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis G Klein, P Delmar, N Voyle, S Rehal, C Hofmann, D Abi-Saab, ... Alzheimer's research & therapy 11, 1-12, 2019	182	2019
Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls BT Darras, R Masson, M Mazurkiewicz-Bełdzińska, K Rose, H Xiong, ... New England Journal of Medicine 385 (5), 427-435, 2021	176	2021
Trial of prasinezumab in early-stage Parkinson’s disease G Pagano, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, ... New England Journal of Medicine 387 (5), 421-432, 2022	171	2022
Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination R Pedotti, JJ DeVoss, S Youssef, D Mitchell, J Wedemeyer, R Madanat, ... Proceedings of the National Academy of Sciences 100 (4), 1867-1872, 2003	162	2003
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects C Sievers, M Meira, F Hoffmann, P Fontoura, L Kappos, RLP Lindberg Clinical immunology 144 (1), 70-79, 2012	155	2012
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial E Bertini, E Dessaud, E Mercuri, F Muntoni, J Kirschner, C Reid, ... The Lancet Neurology 16 (7), 513-522, 2017	131	2017
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled … E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, ... The Lancet Neurology 21 (1), 42-52, 2022	130	2022

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores